Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
6.44
USD
|
+1.74%
|
|
-1.38%
|
+41.54%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
328.8
|
191.1
|
178.7
|
199.8
|
410.9
|
-
|
-
|
Enterprise Value (EV)
1 |
328.8
|
191.1
|
178.7
|
199.8
|
228.7
|
353.3
|
347.6
|
P/E ratio
|
-6
x
|
-3.66
x
|
-3.01
x
|
-5.42
x
|
-5.23
x
|
-3.07
x
|
-3.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
7.96
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
6.74
x
|
EV / EBITDA
|
-
|
-
|
-4.94
x
|
-4.82
x
|
-3.56
x
|
-4.69
x
|
-
|
EV / FCF
|
-
|
-
|
-4,892,455
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
15,356
|
17,710
|
43,269
|
43,906
|
63,800
|
-
|
-
|
Reference price
2 |
21.41
|
10.79
|
4.130
|
4.550
|
6.440
|
6.440
|
6.440
|
Announcement Date
|
3/4/21
|
3/25/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
51.6
|
EBITDA
1 |
-
|
-
|
-36.21
|
-41.45
|
-64.17
|
-75.37
|
-
|
EBIT
1 |
-42.8
|
-50.46
|
-36.53
|
-41.76
|
-82.03
|
-119.9
|
-158.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-307.75%
|
Earnings before Tax (EBT)
1 |
-42.48
|
-50.64
|
-35.36
|
-36.95
|
-80.8
|
-160
|
-158.8
|
Net income
1 |
-42.48
|
-50.64
|
-35.36
|
-36.95
|
-79.88
|
-144.3
|
-172.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-334.88%
|
EPS
2 |
-3.570
|
-2.950
|
-1.370
|
-0.8400
|
-1.232
|
-2.097
|
-2.135
|
Free Cash Flow
|
-
|
-
|
-36.53
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/21
|
3/25/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-14.08
|
-12.49
|
-14.24
|
-17.01
|
-
|
-
|
EBIT
1 |
-16.73
|
-9.086
|
-8.887
|
-8.687
|
-8.513
|
-10.44
|
-7.637
|
-9.62
|
-10.34
|
-14.16
|
-15.3
|
-18.45
|
-23.3
|
-26.15
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-16.8
|
-9.134
|
-8.943
|
-8.667
|
-8.32
|
-9.425
|
-6.526
|
-8.366
|
-9.064
|
-12.99
|
-14.7
|
-17.85
|
-22.7
|
-25.55
|
-
|
Net income
1 |
-16.8
|
-9.134
|
-8.943
|
-8.667
|
-8.32
|
-9.425
|
-6.526
|
-8.366
|
-9.064
|
-12.99
|
-15.2
|
-18.2
|
-22.5
|
-25.6
|
-30
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9200
|
-0.5000
|
-0.4900
|
-0.4700
|
-0.3700
|
-0.2100
|
-0.1500
|
-0.1900
|
-0.2100
|
-0.2900
|
-0.2350
|
-0.2775
|
-0.3400
|
-0.3775
|
-0.4450
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/25/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/14/23
|
5/15/23
|
8/10/23
|
11/14/23
|
3/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
182
|
57.6
|
63.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-36.5
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-40.3%
|
-
|
-62.2%
|
-61.5%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.06
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/21
|
3/25/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
6.44
USD Average target price
19.86
USD Spread / Average Target +208.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +41.54% | 411M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|